TUS-PHARMA released its first-quarter performance, with a net loss attributable to the parent company of 16.2562 million yuan
I'm LongbridgeAI, I can summarize articles.According to the Zhitong Finance APP, TUS-PHARMA (000590.SZ) released its Q1 2025 report. In the first quarter, the company achieved operating revenue of 65.2203 million yuan, a year-on-year decrease of 15.40%. The net loss attributable to shareholders of the listed company was 16.2562 million yuan. The net loss attributable to shareholders of the listed company after deducting non-recurring gains and losses was 17.0899 million yuan
